DUBLIN--(BUSINESS WIRE)--Aug 27, 2018--The "Global Kidney Cancer Therapeutics & Diagnostics Market - Segmented by Cancer Type, Therapy, Diagnostics, End-users, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The market for the period 2018-2023 is expected to register a CAGR of 10.5%.

The growth of the market is mainly driven by factors, such as rising aging population, changes in lifestyle, such as increased intake of alcohol and disproportionate smoking, and government policies to provide better care for Kidney Cancer.

Rising Number of Kidney Cancer Cases

The need for early identification of these diseases will lead to the growth in the market for kidney cancer therapeutics and diagnostics. Increasing detection of presymptomatic tumors by imaging procedures, such as ultrasonography, computed tomography, and magnetic resonance imaging, does not fully explain the upward incidence trends of renal cell carcinoma.

Other factors, such as increased R&D expenditure of pharmaceutical companies and increasing incidences of chronic diseases and aging population will lead to the growth of the market in the forecast period.

Key Highlights

High Cost Associated With Treatment North America to Dominate Market

Notable Developments

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

Bayer F. Hoffmann-La Roche Glaxosmithkline Novartis Pfizer Abbott Laboratories Amgen Genentech Cerulean Pharma Seattle Genetics

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/l7r62j/global_kidney?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180827005413/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Diagnostics,Kidney Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/27/2018 11:35 AM/DISC: 08/27/2018 11:35 AM